The neuropathic pain market is forecast to double from 2006 to reach over $7 billion by 2016. At this time, the current late-stage neuropathic pain pipeline is forecast to take only 18% of the total market share, highlighting an opportunity for better

The neuropathic pain market is forecast to almost triple to over $6.3 billion by the end of the forecast period in 2017. The growth in the market is spurred on by the uptake of Pfizer’s Lyrica (pregabalin), forecast to reach almost $3 billion in

Endometriosis is a painful, menstrual-related disorder that is thought to affect approximately 10% of the female population of reproductive age. Despite this large patient potential, growth of the endometriosis market has been limited by low levels of

This report estimates that Peripheral Neuropathy (PN) and Neuropathic Pain (NP) affect 170 to 270 million individuals globally. PN and NP are causally linked to a number of diseases, however diabetes, cancer and HIV alone are expected to increase the p

This report examines the market critically through a comprehensive review of available information. Sources include industrial databases, commercial news, published reports, economic research and consultation with experts.

With the seven triptan brands continuing to dominate acute migraine treatment and Ortho-McNeil’s Topamax (topiramate) driving sales in the prophylactic market, 7MM revenues of anti-migraine drugs increased by 8.1% from 2005 to $3.7 billion in 200

This 190+ paged report features over 25 tables, and over 40 graphs and figures. The latest news, insights and analysis of the latest developments are included, with an in depth review of the cannabinoids market.

assesses key pain management therapeutics - such as opioids, triptans, anticonvulsants, Cox-II inhibitors and traditional NSAIDs and are discussed in terms of their past, present and future value and the role they are playing in the effective managemen

Postoperative pain can be caused by many different surgical procedures, each involving a variety of complications and physician specialties. Pain is a subjective experience for patients and it would seem that prescribing is driven by physicians` subjec

On 30th September 2004, Merck withdrew its blockbuster drug Vioxx from the global market after trial data reinforced the suspicion that it increased the risk of cardiovascular events. Vioxx was a widely used Cox-2 selective non-steroidal anti-inflammat

The neuropathic pain market has traditionally been a poorly defined area, with widely varying drug classes prescribed. With many drugs now in clinical trials for key neuropathic pain sub-types, pharma companies with powerful marketing arms are expected

Despite being recognized as one of the most common types of pain, few drugs have gained a specific indication for postoperative pain. With most patients still receiving inadequate postoperative pain relief, there is a significant opportunity for manufa

Fueled by the growing interest in neuropathic pain but keen to avoid competition with larger players, small companies recognize the commercial opportunity of the HIV-related neuropathic pain (HIVNP) market. Not only does HIVNP offer a well-served patie

Headache is the most common complaint seen in family practice in the US, yet medical training gives little time to its diagnosis and treatment. Enabling improved diagnosis and an understanding of suitable treatment pathways for migraine will allow phar

Despite millions of patients worldwide, not one neuropathic pain drug company is prioritizing the neuropathic low back pain (NLBP) market. The problem is simply that this patient group is difficult to define in clinical practice. Once diagnosis is made

With millions of diabetes patients suffering from neuropathic pain worldwide and no treatments yet approved for this indication in the US, the diabetic neuropathic pain (DNP) market is set for some dramatic changes. Key market events in the next few y

Following the success of Pfizer`s blockbuster Neurontin (gabapentin), interest in the neuropathic pain market has grown exponentially. The market will continue to grow unabated over the next ten years primarily due to increased public and physician awa

The huge success of Pfizer`s Neurontin (gabapentin) in the neuropathic pain market has encouraged drug manufacturers to explore the potential of their inline and pipeline products in this billion-dollar therapy area. Indeed, as gabapentin finally loses

Across the seven major markets, it is forecast that the prevalence of both the neuropathic and nociceptive markets will increase modestly. It is forecast that the prevalence of the neuropathic pain market will increase to 39.1m individuals, which is co

Neurontin (gabapentin) has finally been knocked off the top spot as a result of fierce generic incursion. However, Pfizer’s follow-on Lyrica (pregabalin), Lilly’s Cymbalta (duloxetine) and Endo/Elan’s Lidoderm (lidocaine patch 5%) are

Surveyed physicians expect to continue to increase their use of Lidoderm in post-herpetic neuralgia and a variety of off-label pain conditions with use varying by specialty.

In spite of generic Actiq competition, Cephalon’s reign of the breakthrough pain market will be secured in the short-term with sales of its follow-on brand Fentora. From 2008, however, a number of fast-acting analgesics will enter the arena and b

After the launch of Trexima in 2007, triptan genericization coupled with a weak late-stage pipeline will result in a major shift in market dynamics, and will result in the migraine market value decreasing to $3.2 billion in 2015. The market remains rec